Viatris (VTRS) 2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-26) + Yahoo Finance

Auditor: Deloitte & Touche LLP — Clean opinion (1 Critical Audit Matter on Goodwill)

One-line verdict: Viatris recorded a $3.51B net loss on $14.30B of revenue, down 3% YoY, after a $2.94B Q1 goodwill impairment wiped out the entire JANZ reporting unit and carved into North America ($707M), Europe ($1,554M), JANZ ($301M), and Emerging Markets ($375M). The company's flagship Indore, India manufacturing facility has been under an FDA warning letter and import alert since 2023, costing an estimated $370M in lost 2025 revenue. In February 2026 a fire broke out at the Nashik, India oral-solid-dose facility and manufacturing was "temporarily suspended" at filing date with an April 2026 restart target. Two red flags flash on the screen (C4 cash-to-debt 10%, D1 goodwill/intangibles 149% of equity), but the real story is four watch flags in different directions: B2 CapEx growth 29.5% on a revenue DECLINE, B3 SG&A at 75.7% of gross profit, C1 CFFO/Net Income of -0.66 (operating cash inverted from loss), and D2 interest coverage at 0.5x which signals financial stress per the screening engine. The Altman Z-Score is 0.55 — distress zone. Operating cash flow of $2.32B (essentially flat) is the only thing keeping the company liquid enough to cover $600M in dividends and $500M in buybacks.

The $2.94B Goodwill Impairment

From the MD&A, explaining the Q1 2025 trigger event: "During the first quarter of 2025, the Company experienced a sharp and sustained decline in its share price and significantly increased uncertainty and volatility in the geopolitical and economic environments in which the Company operates. As a result of these factors, the Company determined that a triggering event had occurred for each of its reporting units and performed an interim goodwill impairment test as of March 31, 2025 and recorded a non-cash goodwill impairment charge of $2.94 billion as a result of the interim goodwill impairment test performed."

Per Deloitte's Critical Audit Matter: "As of March 31, 2025, the Company had approximately $9.4 billion of consolidated goodwill, which was allocated to its North America ($3.1 billion), Europe ($3.9 billion), Greater China ($0.9 billion), JANZ ($0.3 billion), and Emerging Markets ($1.2 billion) reporting units prior to any impairment charges... During the quarter ended March 31, 2025, the Company recorded goodwill impairment charges for the North America ($707.0 million), Europe ($1,554.0 million), JANZ ($300.8 million), and Emerging Markets ($375.0 million) reporting units, for a total of $2.9 billion."

JANZ (Japan/Australia/New Zealand) was wiped out entirely: "As a result of this impairment, there was no remaining goodwill in the JANZ reporting unit." That is the rare case of a full goodwill write-off of a reporting segment.

And the warning on Greater China: "The fair value of the Greater China reporting unit exceeded its carrying value by approximately $322 million, or 5.8% as of March 31, 2025 and April 1, 2025. Given that the reporting units revenues are sensitive to the potential for continued or additional drug pricing reduction pressures, general uncertainty related to timing of responses and approvals from the FDA..." — Greater China has only 5.8% headroom before another impairment.

Segments, Fifteen Months of Setbacks

Per the Results of Operations table:

Greater China was the only segment with positive growth — a remarkable inversion for a U.S.-based generics company. The MD&A decomposes the decline: "Net sales decreased by approximately $478.0 million, or 3%, due to the inclusion of net sales in the prior year period related to divestitures that closed during 2024." Of the $465.8M in base business erosion, "approximately $370 million related to the Indore Impact." That is 79% of all base business erosion traced to one FDA warning letter.

Results of Operations: Losses Everywhere

Per the financial summary in MD&A:

Gross profit collapsed $610M on a $439M revenue decline — meaning every dollar of revenue loss cost Viatris $1.39 in gross profit. R&D expense JUMPED 19% to $965.9M due to "higher expenses for the selatogrel and cenerimod development programs" (Idorsia acquisition). This is a declining-revenue generics company spending harder on innovative pipeline while base business erodes — the classic specialty generics squeeze.

Adjusted gross margin fell from 58% to 56% — a quiet two-point compression that happens when pricing pressure outruns cost absorption.

Cash Flow: The Only Thing Holding the Balance Sheet Together

Per the MD&A Liquidity section:

The MD&A: "Net cash provided by operating activities increased by $13.0 million to $2.32 billion for the year ended December 31, 2025, as compared to net cash provided by operating activities of $2.30 billion for the year ended December 31, 2024... The increase in net cash provided by operating activities was principally due to the timing of cash payments and collections, partially offset by lower operating earnings."

CFFO is essentially flat. The $2.94B goodwill impairment is a non-cash charge, so it doesn't affect CFFO — but the deteriorating gross profit does. The screening engine flags C1 (CFFO/NI = -0.66) as a watch — but that's a misreading because NI is negative. In underlying terms, operating cash conversion is actually strong: CFFO of $2.32B against adjusted net income would still be at or above 1.0x. The problem is the GAAP loss.

Viatris paid $561M in dividends while reporting a $3.51B loss and repurchased $500M of stock. Free cash flow of $1.94B barely covers these $1.06B in shareholder returns, leaving ~$880M for deleveraging. The debt pile remains $14.7B against $1.5B of cash.

2026 CapEx guidance: "approximately $350 million to $450 million" — essentially flat with 2025 levels.

The Indore Warning Letter Is Now Year Two of Pain

Per the MD&A: "While product continues to be shipped from the Indore facility to markets outside the U.S., as expected, we have also experienced a negative impact in other markets during 2025, including the ARV business in Emerging Markets and select generic products in Europe. The estimated negative impact to total revenues for the year ended December 31, 2025 versus the year ended December 31, 2024 was approximately $370 million."

And the facility status: "The facility will be subject to a reinspection by the FDA. The timing of the reinspection will be determined by the FDA; however, we anticipate that the facility will be ready for reinspection in 2026."

Translation: Viatris has been under FDA warning letter / import alert for the Indore plant for well over a year. A 2026 reinspection is "anticipated" — not scheduled — and re-inspection does not guarantee clearance. Until clearance, U.S. revenue from Indore products remains zero.

And Now Nashik Is on Fire

From the MD&A: "In mid-February 2026, a fire occurred in a service area at the Company's oral solid dose manufacturing facility in Nashik, India. Manufacturing at the facility has been temporarily suspended and the Company currently expects to resume operations beginning in April 2026. The Company believes it has certain insurance coverages for losses, including for assets and business interruption. In the event the plant cannot be returned to normal operations or the Company's insurance coverage is unavailable or inadequate, this event could have a negative impact on our financial position, results of operations and cash flows."

Nashik is Viatris's oral-solid-dose facility — the most important dosage form in its generics catalog. Two of India's largest Viatris manufacturing sites are simultaneously producing below capacity as of the filing date.

The 18-Point Screening

Beneish M-Score components:

The M-Score of -3.25 is defensively low — shrinking companies rarely trigger Beneish. The real warning is Altman Z at 0.55, which the formula penalizes for equity destruction from impairment.

Key Risks from the 10-K

1. Strategic Review and Restructuring Uncertainty

Per Item 1A Risk Factors: "We may not realize the intended benefits of, or achieve the intended goals or outlooks with respect to, our strategic initiatives and priorities, including our enterprise-wide strategic review and other potential corporate transactions. Viatris restructuring activities may not achieve their intended goals and may present significant challenges."

2. Tariff and Trade Restriction Risk

Per Item 1A: "The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business, as well as any retaliatory actions... could have a material adverse effect on our business." For a company that manufactures most of its active pharmaceutical ingredients in India and sells heavily to the U.S. and Europe, tariffs are not hypothetical.

3. Pricing Pressure and Reimbursement Controls

Per Item 1A: "We have and may continue to experience pressure on the pricing of and reimbursements for certain of our products due to pricing controls, social or government pressure to lower the cost of drugs, and consolidation across the supply chain."

4. Regulatory and Manufacturing Risk (Indore / Nashik)

Per the MD&A: "While product continues to be shipped from the Indore facility to markets outside the U.S., as expected, we have also experienced a negative impact in other markets during 2025... In mid-February 2026, a fire occurred in a service area at the Company's oral solid dose manufacturing facility in Nashik, India."

5. Acquisition Charges and Goodwill Impairments

Per Item 1A: "Charges to earnings resulting from acquisitions could have a material adverse effect on our business." Realized in 2025 for $2.94B. Greater China is next in line with only 5.8% of fair value cushion per Deloitte's CAM.

6. Going-Concern-Adjacent Financial Profile

Per the 10-K: $14.7B of debt, $1.5B of cash, negative interest coverage issues, Z-Score of 0.55. Viatris is not technically in distress — CFFO supports dividends, buybacks, debt service — but there is zero operational cushion. Per the MD&A: "Our ability to satisfy our working capital requirements and debt service obligations, and fund planned capital expenditures, share repurchases, or dividend payments, will substantially depend upon our future operating performance (which will be affected by prevailing economic conditions)."

Key Financial Trends (3-Year)

Summary

Grade: F. Two structural red flags and four watch flags, plus an Altman Z-Score in the distress zone.

Viatris is a specialty generics company with ~$14.3B revenue and ~$2.3B of operating cash flow that is spending most of its free cash flow on dividends ($561M) and buybacks ($500M) rather than reducing its $14.7B debt stack. The 2025 10-K documented:

Red flags + watches:

What the grade does NOT mean: The business is not bankrupt. CFFO supports the debt. Deloitte issued an unqualified opinion. The Beneish M-Score of -3.25 is very low — this is not a manipulation story, it's a business deterioration story. The F-Score of 1.57 implies only 0.57% probability of fraud.

What would change our view: Indore reinspection and clearance, Nashik returned to service with quantified insurance recovery, sustained gross margin stabilization, and a clear deleveraging plan replacing the buyback program.

What the filing does NOT tell us: Whether the 2026 strategic review concludes with a spin-off, merger, or status quo. The 10-K repeatedly mentions the enterprise-wide strategic review as an ongoing process.

Read the 10-K. Read Deloitte's CAM on goodwill. Read the Nashik disclosure. Then decide.

**Disclaimer**: This report is based on Viatris's fiscal year 2025 10-K filed with the SEC on February 26, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade F means major red flags were detected that warrant thorough investigation.